concept

DONANEMAB

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DONANEMAB: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

97Connections
0Hypotheses
4Analyses
50Outgoing
25Incoming
0Experiments
5Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info
NameDONANEMAB
Key Genes/ProteinsAMYLOID, AMYLOID-BETA, APOE, APP
Related DiseasesALZHEIMER, ALZHEIMER'S DISEASE, AMYLOID PLAQUES, AUTOPHAGY, COGNITIVE DECLINE

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Donanemab Dosing Regimens Phase 3 for Early Alzheimer's (NCT05738486)

clinical · 1337 words

Pathway Diagram

graph TD
    DONANEMAB["DONANEMAB"]
    DONANEMAB -->|"treats"| Cognitive_Decline["Cognitive Decline"]
    DONANEMAB -->|"targets"| Amyloid_Beta["Amyloid Beta"]
    DONANEMAB -->|"targets"| Amyloid__["Amyloid-beta"]
    DONANEMAB -->|"binds_to"| amyloid__["amyloid-beta"]
    DONANEMAB -->|"treats"| Alzheimer_s_disease["Alzheimer's disease"]
    DONANEMAB -->|"targets"| AMYLOID_BETA["AMYLOID-BETA"]
    DONANEMAB -->|"treats"| Early_Stage_Alzheimer_s_Diseas["Early-Stage Alzheimer's Disease"]
    ADUCANUMAB["ADUCANUMAB"] -->|"target for"| DONANEMAB
    AMYLOID["AMYLOID"] -->|"implicated in"| DONANEMAB

Outgoing (72)

TargetRelationTypeStr
amyloid_plaquesclearspathological_structure0.00
ad_clinical_trial_failures:donanemabdata_indataset_row0.00
ad_clinical_trial_failures:donanemabdata_indataset_row0.00
Cognitive Declinetreatsphenotype0.95
Amyloid βtargetsprotein0.95

Incoming (25)

SourceRelationTypeStr
ad_clinical_trial_failures:donanemabdata_indataset_row0.00
ad_clinical_trial_failures:donanemabdata_indataset_row0.00
37459141significantly slowedpaper0.90
37459141increased risk ofpaper0.90
37459141achieved treatment effect inpaper0.90

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (4)

Scientific analyses that reference this entity

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.585

What amyloid threshold level is required for optimal clinical benefit in early A

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.577

Why have numerous phase 3 clinical trials failed despite advances in understandi

neurodegeneration | 2026-04-12 | 1 hypotheses Top: 0.566

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 14 hypotheses Top: 0.773

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (5)

Multi-agent debates referencing this entity

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

Hypothesis debate: Multi-Biomarker Composite Index Surpassing Amyloid PET for Tr

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

While the study demonstrates dose-response relationships between amyloid levels

closed · Rounds: 4 · Score: 0.76 · 2026-04-16

Why have numerous phase 3 clinical trials failed despite advances in understandi

closed · Rounds: 5 · Score: 0.67 · 2026-04-12

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

closed · Rounds: 4 · Score: 0.91 · 2026-04-06

Related Research

Hypotheses and analyses mentioning DONANEMAB in their description or question text

No additional research found